Canada Markets close in 1 hr 13 mins
  • S&P/TSX

    21,637.54
    -15.48 (-0.07%)
     
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • DOW

    35,870.95
    -60.10 (-0.17%)
     
  • CAD/USD

    0.7936
    -0.0001 (-0.0095%)
     
  • BTC-CAD

    73,682.71
    -995.63 (-1.33%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • GOLD FUTURES

    1,861.20
    -0.20 (-0.01%)
     
  • RUSSELL 2000

    2,363.59
    -13.42 (-0.56%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • NASDAQ

    15,993.71
    +72.14 (+0.45%)
     
  • VOLATILITY

    17.59
    +0.48 (+2.81%)
     
  • FTSE

    7,255.96
    -35.24 (-0.48%)
     
  • NIKKEI 225

    29,683.09
    +84.43 (+0.29%)
     
  • CAD/EUR

    0.6979
    +0.0004 (+0.06%)
     

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2021 financial results and operational highlights in a conference call on November 4, 2021 at 8 a.m. ET.

To join the call:

  • U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.

  • Please visit this link for a simultaneous live webcast of the call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on November 4, 2021 at 12 p.m. ET.

About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. To fully realize the transformative potential of CRISPR/Cas9, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of CRISPR/Cas9 to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatweets.

Intellia Contacts:

Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
ian.karp@intelliatx.com

Lina Li
Director, Investor Relations
+1-857-706-1612
lina.li@intelliatx.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting